R64
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 52
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.380
- INTERFERON_ALPHA_RESPONSE+0.320
- CHOLESTEROL_HOMEOSTASIS+0.180
- INTERFERON_GAMMA_RESPONSE+0.180
- UNFOLDED_PROTEIN_RESPONSE+0.140
- BILE_ACID_METABOLISM+0.130
- DNA_REPAIR+0.090
- KRAS_SIGNALING_DN+0.050
- PANCREAS_BETA_CELLS+0.040
- E2F_TARGETS+0.030
Top 10 suppressed
- PROTEIN_SECRETION-0.490
- UV_RESPONSE_DN-0.400
- TNFA_SIGNALING_VIA_NFKB-0.390
- KRAS_SIGNALING_UP-0.370
- ANGIOGENESIS-0.360
- TGF_BETA_SIGNALING-0.360
- ANDROGEN_RESPONSE-0.350
- IL2_STAT5_SIGNALING-0.310
- NOTCH_SIGNALING-0.300
- HYPOXIA-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR26320093 | — | — | 0.861 |
| 2 | SRR4195696 | — | — | 0.819 |
| 3 | SRR1516061 | — | — | 0.815 |
| 4 | SRR8942965 | — | — | 0.805 |
| 5 | TCGA-GV-A6ZA-01A-12R-A33J-07 | — | — | 0.802 |
| 6 | SRR650171 | — | — | 0.799 |
| 7 | TCGA-GD-A6C6-01A-21R-A31N-07 | — | — | 0.796 |
| 8 | TCGA-P3-A6SW-01A-11R-A34R-07 | — | — | 0.794 |
| 9 | R175 | — | — | 0.789 |
| 10 | 54f66d7c-b022-4df2-830d-48d55791c80e | — | — | 0.785 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.320 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.040 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.030 | Inavolisib | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.010 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.010 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |